920436
NanoFabTx™ PEG-PLA drug formulation screening kit
for synthesis of PEGylated nanoparticles
Synonyme(s) :
Microfluidics, NanoFabTx™ reagent kit, Nanoformulation, Nanoparticle kit, PEG-PLA
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
NACRES:
NA.23
UNSPSC Code:
12161503
Storage temp.:
2-8°C
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderQuality Level
description
Kit components :
PEGPLA-L-M (919942-500mg)
PEGPLA-H-M (919934-500mg)
Stabilizer-Nano (907766-5g), PEG-PLA drug formulation screening kit, for synthesis of PEGylated PLA nanoparticles
application(s)
advanced drug delivery
storage temp.
2-8°C
General description
NanoFabTx™ PEG-PLA drug formulation screening kit is a nanoformulation kit containing rationally selected PEGylated PLA polymers that have been used widely for controlled drug release of many different types of therapeutic molecules. The kit contains protocols for two different particle synthesis methods:
- A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
- A Microfluidics protocol using commercial platforms or syringe pumps.
Application
NanoFabTx™ PEG-PLA drug formulation screening kit enables users to encapsulate a wide variety of therapeutic drug molecules in specifically sized, biodegradable, PEGylated PLA nanoparticles. By simplifying the chemistry and providing an easy-to-use toolkit with step-by-step instructions, our NanoFabTx™ nanoformulation screening kit helps researchers achieve reproducible synthesis of drug encapsulating nanoparticles with narrow size dispersity, eliminating the need for lengthy trial-and-error optimization. Suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery, PEG-PLA nanoparticles, made using the NanoFabTx™ PEG-PLA drug formulation screening kit, are designed for maximizing the encapsulation of hydrophobic drugs to minimize the time and expensive wasted reagents of synthetic optimization.
Features and Benefits
- Includes tested protocols with step-by-step instructions for nanoprecipitation or microfluidics-based syntheses
- Requires minimal laboratory setup
- Optimized to achieve monodisperse, homogenously shaped, biodegradable, PEGylated PLA nanoparticles in any size between 60 and 100 nm
- Formulated to maximize the encapsulation of hydrophobic drugs
- Includes two different PEGylated PLAs
Legal Information
NANOFABTX is a trademark of Sigma-Aldrich Co. LLC
Classe de stockage
10 - Combustible liquids
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Articles
Professor Robert K. Prud’homme introduces flash nanoprecipitation (FNP) for nanoparticle fabrication, which is a scalable, rapid mixing process for nanoparticle formulations.
NanoFabTx™ platform accelerates drug development with ready-to-use formulations and microfluidic devices for particle synthesis.
NanoFabTX kits enable precise drug delivery with lipid nanoparticles and liposomes for mRNA and nucleic acids.
Contenu apparenté
Solène Passemard et al.
Biomacromolecules, 18(9), 2747-2755 (2017-07-26)
The production of hydrogel microspheres (MS) for cell immobilization, maintaining the favorable properties of alginate gels but presenting enhanced performance in terms of in vivo durability and physical properties, is desirable to extend the therapeutic potential of cell transplantation. A
Xu Jia et al.
ACS biomaterials science & engineering, 2(9), 1641-1648 (2016-09-12)
Theranostic nanomedicine has recently emerged as an appealing approach for tumor chemotherapy. Here, for the first time, fluorescent carbon dots (Cdots) were used as cross-linker for tumor theranostic nanoparticles. Novel theranostic nanoparticles of approximately 27 nm with a doxorubicin (DOX)
Redouan Mahou et al.
Materials (Basel, Switzerland), 7(1), 275-286 (2014-01-09)
The progress of medical therapies, which rely on the transplantation of microencapsulated living cells, depends on the quality of the encapsulating material. Such material has to be biocompatible, and the microencapsulation process must be simple and not harm the cells.
Numéro d'article de commerce international
| Référence | GTIN |
|---|---|
| 920436-1KT | 04065266037487 |